{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:11:03Z","timestamp":1788379863425,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s12325-024-02869-y","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T08:01:31Z","timestamp":1716278491000},"page":"2808-2825","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetic Comparison of a Fixed-Dose Combination of Candesartan Cilexetil\/Amlodipine\/Atorvastatin Versus Co-administration of Individual Formulations in Healthy Participants"],"prefix":"10.1007","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct04478097","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04627207","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5643-0913","authenticated-orcid":false,"given":"Jae Hoon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3952-5096","authenticated-orcid":false,"given":"Ji Hye","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8812-412X","authenticated-orcid":false,"given":"MinYoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0623-5455","authenticated-orcid":false,"given":"Jang Hee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8801-0323","authenticated-orcid":false,"given":"Jung","family":"Sunwoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2591-4867","authenticated-orcid":false,"given":"Jin-Gyu","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"2869_CR1","unstructured":"Federal Interagency Forum on Aging-Related Statistics. Older Americans 2016: key indicators of well-being. 2016. https:\/\/agingstats.gov\/docs\/LatestReport\/Older-Americans-2016-Key-Indicators-of-WellBeing.pdf. Accessed 2 Apr 2024."},{"key":"2869_CR2","doi-asserted-by":"publisher","unstructured":"Collerton J, Davies K, Jagger C, et al. Health and disease in 85\u00a0year olds: baseline findings from the Newcastle 85+ cohort study. BMJ. 2012;345:e4462\u2013e4462. https:\/\/doi.org\/10.1136\/bmj.e4462.","DOI":"10.1136\/bmj.e4462"},{"issue":"3","key":"2869_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/17843286.2016.1148298","volume":"71","author":"M Wauters","year":"2016","unstructured":"Wauters M, Elseviers M, Vaes B, et al. Polypharmacy in a Belgian cohort of community-dwelling oldest old (80+). Acta Clin Belg. 2016;71(3):158\u201366. https:\/\/doi.org\/10.1080\/17843286.2016.1148298.","journal-title":"Acta Clin Belg"},{"issue":"6","key":"2869_CR4","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/pds.3772","volume":"24","author":"M Herr","year":"2015","unstructured":"Herr M, Robine JM, Pinot J, Arvieu JJ, Ankri J. Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people. Pharmacoepidemiol Drug Saf. 2015;24(6):637\u201346. https:\/\/doi.org\/10.1002\/pds.3772.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"2869_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s40266-014-0165-5","volume":"31","author":"B Hovstadius","year":"2014","unstructured":"Hovstadius B, Petersson G, Hellstr\u00f6m L, Ericson L. Trends in inappropriate drug therapy prescription in the elderly in Sweden from 2006 to 2013: assessment using national indicators. Drugs Aging. 2014;31(5):379\u201386. https:\/\/doi.org\/10.1007\/s40266-014-0165-5.","journal-title":"Drugs Aging"},{"key":"2869_CR6","first-page":"59","volume":"13","author":"F Guerriero","year":"2015","unstructured":"Guerriero F, Orlando V, Tari DU, et al. How healthy is community-dwelling elderly population? Results from Southern Italy. Transl Med UniSA. 2015;13:59\u201364.","journal-title":"Transl Med UniSA"},{"issue":"2","key":"2869_CR7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/pds.4142","volume":"26","author":"KH Halvorsen","year":"2017","unstructured":"Halvorsen KH, Selbaek G, Ruths S. Trends in potentially inappropriate medication prescribing to nursing home patients: comparison of three cross-sectional studies. Pharmacoepidemiol Drug Saf. 2017;26(2):192\u2013200. https:\/\/doi.org\/10.1002\/pds.4142.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2869_CR8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/1756-0500-7-340","volume":"7","author":"CS Tsoi","year":"2014","unstructured":"Tsoi CS, Chow JY, Choi KS, et al. Medical characteristics of the oldest old: retrospective chart review of patients aged 85+ in an academic primary care centre. BMC Res Notes. 2014;7:340. https:\/\/doi.org\/10.1186\/1756-0500-7-340.","journal-title":"BMC Res Notes"},{"issue":"1","key":"2869_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/fampra\/cml067","volume":"24","author":"U Junius-Walker","year":"2007","unstructured":"Junius-Walker U, Theile G, Hummers-Pradier E. Prevalence and predictors of polypharmacy among older primary care patients in Germany. Fam Pract. 2007;24(1):14\u20139. https:\/\/doi.org\/10.1093\/fampra\/cml067.","journal-title":"Fam Pract"},{"issue":"6","key":"2869_CR10","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2174\/092986710790416326","volume":"17","author":"A Corsonello","year":"2010","unstructured":"Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem. 2010;17(6):571\u201384. https:\/\/doi.org\/10.2174\/092986710790416326.","journal-title":"Curr Med Chem"},{"issue":"22","key":"2869_CR11","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1511939.","journal-title":"N Engl J Med"},{"issue":"9836","key":"2869_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0140-6736(12)60240-2","volume":"380","author":"K Barnett","year":"2012","unstructured":"Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(12)60240-2.","journal-title":"Lancet"},{"key":"2869_CR13","doi-asserted-by":"publisher","first-page":"e6341","DOI":"10.1136\/bmj.e6341","volume":"345","author":"B Guthrie","year":"2012","unstructured":"Guthrie B, Payne K, Alderson P, McMurdo ME, Mercer SW. Adapting clinical guidelines to take account of multimorbidity. BMJ. 2012;345:e6341. https:\/\/doi.org\/10.1136\/bmj.e6341.","journal-title":"BMJ"},{"issue":"4","key":"2869_CR14","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/jgs.14682","volume":"65","author":"BC Wimmer","year":"2017","unstructured":"Wimmer BC, Cross AJ, Jokanovic N, et al. Clinical outcomes associated with medication regimen complexity in older people: a systematic review. J Am Geriatr Soc. 2017;65(4):747\u201353. https:\/\/doi.org\/10.1111\/jgs.14682.","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"2869_CR15","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1001\/archinte.165.10.1147","volume":"165","author":"RH Chapman","year":"2005","unstructured":"Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165(10):1147\u201352. https:\/\/doi.org\/10.1001\/archinte.165.10.1147.","journal-title":"Arch Intern Med"},{"issue":"12","key":"2869_CR16","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874\u20132071. https:\/\/doi.org\/10.1097\/HJH.0000000000003480.","journal-title":"J Hypertens"},{"issue":"9","key":"2869_CR17","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1097\/HJH.0000000000003497","volume":"41","author":"F Rea","year":"2023","unstructured":"Rea F, Morabito G, Savar\u00e9 L, Pathak A, Corrao G, Mancia G. Adherence and related cardiovascular outcomes to single pill vs. separate pill administration of antihypertensive triple-combination therapy. J Hypertens. 2023;41(9):1466\u201373. https:\/\/doi.org\/10.1097\/HJH.0000000000003497.","journal-title":"J Hypertens"},{"issue":"8","key":"2869_CR18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMsa1616035","volume":"377","author":"AP Bress","year":"2017","unstructured":"Bress AP, Bellows BK, King JB, et al. Cost-effectiveness of intensive versus standard blood-pressure control. N Engl J Med. 2017;377(8):745\u201355. https:\/\/doi.org\/10.1056\/NEJMsa1616035.","journal-title":"N Engl J Med"},{"issue":"5","key":"2869_CR19","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1001\/jamacardio.2016.5837","volume":"2","author":"IB Richman","year":"2017","unstructured":"Richman IB, Owens DK, Goldhaber-Fiebert J. Cost-effectiveness of intensive blood pressure management\u2014is there an additional price to pay?\u2014reply. JAMA Cardiol. 2017;2(5):581\u20132. https:\/\/doi.org\/10.1001\/jamacardio.2016.5837.","journal-title":"JAMA Cardiol"},{"issue":"12","key":"2869_CR20","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1161\/CIRCULATIONAHA.117.027067","volume":"136","author":"DJ Heller","year":"2017","unstructured":"Heller DJ, Coxson PG, Penko J, et al. Evaluating the impact and cost-effectiveness of statin use guidelines for primary prevention of coronary heart disease and stroke. Circulation. 2017;136(12):1087\u201398. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.027067.","journal-title":"Circulation"},{"issue":"2","key":"2869_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1161\/CIRCOUTCOMES.108.808469","volume":"2","author":"B Mihaylova","year":"2009","unstructured":"Mihaylova B, Briggs A, Hlatky M, et al. Heart Protection Study Collaborative Group Statin cost-effectiveness in the United States for people at different vascular risk levels. Circ Cardiovasc Qual Outcomes. 2009;2(2):65\u201372. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.108.808469.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"596","key":"2869_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3399\/bjgp12X630232","volume":"62","author":"T McCormack","year":"2012","unstructured":"McCormack T, Krause T, O\u2019Flynn N. Management of hypertension in adults in primary care: NICE guideline: NICE guideline. Br J Gen Pract. 2012;62(596):163\u20134. https:\/\/doi.org\/10.3399\/bjgp12X630232.","journal-title":"Br J Gen Pract"},{"issue":"1","key":"2869_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1161\/01.hyp.25.1.14","volume":"25","author":"E Delacr\u00e9taz","year":"1995","unstructured":"Delacr\u00e9taz E, Nussberger J, Biollaz J, Waeber B, Brunner HR. Characterization of the angiotensin\u00a0II receptor antagonist TCV-116 in healthy volunteers. Hypertension. 1995;25(1):14\u201321. https:\/\/doi.org\/10.1161\/01.hyp.25.1.14.","journal-title":"Hypertension"},{"key":"2869_CR24","first-page":"S24","volume":"55","author":"M Burnier","year":"1996","unstructured":"Burnier M, Buclin T, Biollaz J, Nussberger J, Waeber B, Brunner HR. Pharmacokinetic-pharmacodynamic relationships of three angiotensin\u00a0II receptor antagonists in normal volunteers. Kidney Int Suppl. 1996;55:S24\u20139.","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"2869_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/08037050152518302","volume":"3","author":"T Unger","year":"2001","unstructured":"Unger T. Pharmacology of AT1-receptor blockers. Blood Press Suppl. 2001;3(3):5\u201310. https:\/\/doi.org\/10.1080\/08037050152518302.","journal-title":"Blood Press Suppl"},{"issue":"12","key":"2869_CR26","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S0895-7061(99)00142-9","volume":"12","author":"Y Lacourci\u00e8re","year":"1999","unstructured":"Lacourci\u00e8re Y, Asmar R, Investi CLS. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Am J Hypertens. 1999;12(12):1181\u20137. https:\/\/doi.org\/10.1016\/S0895-7061(99)00142-9.","journal-title":"Am J Hypertens"},{"issue":"7","key":"2869_CR27","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2217\/cer-2017-0063","volume":"7","author":"L Zhang","year":"2018","unstructured":"Zhang L, Yang J, Li L, et al. Comparison of amlodipine versus other calcium channel blockers on blood pressure variability in hypertensive patients in China: a retrospective propensity score-matched analysis. J Comp Eff Res. 2018;7(7):651\u201360. https:\/\/doi.org\/10.2217\/cer-2017-0063.","journal-title":"J Comp Eff Res"},{"issue":"1","key":"2869_CR28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3904\/kjim.2019.308","volume":"36","author":"SE Kim","year":"2021","unstructured":"Kim SE, Jo SH, Han SH, et al. Comparison of calcium-channel blockers for long-term clinical outcomes in patients with vasospastic angina. Korean J Intern Med. 2021;36(1):124\u201334. https:\/\/doi.org\/10.3904\/kjim.2019.308.","journal-title":"Korean J Intern Med"},{"issue":"suppl 1","key":"2869_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2165\/00003495-200767001-00007","volume":"67","author":"M Arca","year":"2007","unstructured":"Arca M. Atorvastatin: a safety and tolerability profile. Drugs. 2007;67(suppl 1):63\u20139. https:\/\/doi.org\/10.2165\/00003495-200767001-00007.","journal-title":"Drugs"},{"issue":"25","key":"2869_CR30","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;139(25):e1082\u2013143. https:\/\/doi.org\/10.1161\/CIR.0000000000000625.","journal-title":"Circulation"},{"key":"2869_CR31","volume-title":"Lipitor\u00ae (atorvastatin calcium) label","author":"Food and Drug Administration","year":"1996","unstructured":"Food and Drug Administration. Lipitor\u00ae (atorvastatin calcium) label. Washington, DC: FDA; 1996."},{"issue":"1","key":"2869_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0009-9236(98)90023-6","volume":"64","author":"T Kantola","year":"1998","unstructured":"Kantola T, Kivist\u00f6 KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther. 1998;64(1):58\u201365. https:\/\/doi.org\/10.1016\/S0009-9236(98)90023-6.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"2869_CR33","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1053\/cp.1999.v66.100453001","volume":"66","author":"JJ Lilja","year":"1999","unstructured":"Lilja JJ, Kivist\u00f6 KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther. 1999;66(2):118\u201327. https:\/\/doi.org\/10.1053\/cp.1999.v66.100453001.","journal-title":"Clin Pharmacol Ther"},{"key":"2869_CR34","unstructured":"McIver LA, Siddique MS. Atorvastatin. [Updated 2022 Nov 13]. Treasure Island: StatPearls; 2023."},{"issue":"1","key":"2869_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2165\/00003088-200241010-00002","volume":"41","author":"CH Gleiter","year":"2002","unstructured":"Gleiter CH, M\u00f6rike KE. Clinical pharmacokinetics of candesartan. Clin Pharmacokinet. 2002;41(1):7\u201317. https:\/\/doi.org\/10.2165\/00003088-200241010-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2869_CR36","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2165\/00003088-199222010-00003","volume":"22","author":"PA Meredith","year":"1992","unstructured":"Meredith PA, Elliott HL. Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet. 1992;22(1):22\u201331. https:\/\/doi.org\/10.2165\/00003088-199222010-00003.","journal-title":"Clin Pharmacokinet"},{"issue":"13","key":"2869_CR37","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.2165\/00003088-200342130-00005","volume":"42","author":"H Lennern\u00e4s","year":"2003","unstructured":"Lennern\u00e4s H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet. 2003;42(13):1141\u201360. https:\/\/doi.org\/10.2165\/00003088-200342130-00005.","journal-title":"Clin Pharmacokinet"},{"key":"2869_CR38","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.2147\/DDDT.S172568","volume":"12","author":"JR Kim","year":"2018","unstructured":"Kim JR, Kim S, Huh W, Ko JW. No pharmacokinetic interactions between candesartan and amlodipine following multiple oral administrations in healthy subjects. Drug Des Dev Ther. 2018;12:2475\u201383. https:\/\/doi.org\/10.2147\/DDDT.S172568.","journal-title":"Drug Des Dev Ther"},{"issue":"3","key":"2869_CR39","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/cpdd.727","volume":"9","author":"S Kim","year":"2020","unstructured":"Kim S, Ko JW, Kim JR. Pharmacokinetic and safety profiles of a fixed-dose combination of amlodipine, valsartan, and atorvastatin: a 3-period replicate crossover study. Clin Pharmacol Drug Dev. 2020;9(3):386\u201394. https:\/\/doi.org\/10.1002\/cpdd.727.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2869_CR40","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.2147\/DDDT.S233732","volume":"14","author":"JG Hwang","year":"2020","unstructured":"Hwang JG, Yu KS, Lee S. Comparison of the pharmacokinetics of highly variable drugs in healthy subjects using a partial replicated crossover study: a fixed-dose combination of fimasartan 120\u00a0mg and atorvastatin 40\u00a0mg versus separate tablets. Drug Des Dev Ther. 2020;14:1953\u201361. https:\/\/doi.org\/10.2147\/DDDT.S233732.","journal-title":"Drug Des Dev Ther"},{"key":"2869_CR41","volume-title":"Guideline on the investigation of bioequivalence","author":"Committee for Medicinal Products for Human Use","year":"2010","unstructured":"Committee for Medicinal Products for Human Use. Guideline on the investigation of bioequivalence. London: European Medicines Agency; 2010."},{"key":"2869_CR42","volume-title":"Guidance for industry: statistical approaches to establishing bioequivalence","author":"Food and Drug Administration","year":"2001","unstructured":"Food and Drug Administration. Guidance for industry: statistical approaches to establishing bioequivalence. Washington, DC: FDA; 2001."},{"key":"2869_CR43","unstructured":"Ministry of Food and Drug Safety. Standards on the equivalency study of drug. Cheongju: MFDS; 2023."},{"issue":"1","key":"2869_CR44","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11095-007-9434-x","volume":"25","author":"SH Haidar","year":"2008","unstructured":"Haidar SH, Davit B, Chen ML, et al. Bioequivalence approaches for highly variable drugs and drug products. Pharm Res. 2008;25(1):237\u201341. https:\/\/doi.org\/10.1007\/s11095-007-9434-x.","journal-title":"Pharm Res"},{"issue":"10","key":"2869_CR45","doi-asserted-by":"publisher","first-page":"485","DOI":"10.5414\/cpp43485","volume":"43","author":"KK Midha","year":"2005","unstructured":"Midha KK, Rawson MJ, Hubbard JW. The bioequivalence of highly variable drugs and drug products. Int J Clin Pharmacol Ther. 2005;43(10):485\u201398. https:\/\/doi.org\/10.5414\/cpp43485.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2869_CR46","volume-title":"Draft guidance on atorvastatin calcium","author":"Food and Drug Administration","year":"2010","unstructured":"Food and Drug Administration. Draft guidance on atorvastatin calcium. Washington, DC: FDA; 2010."},{"key":"2869_CR47","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.2147\/DDDT.S193254","volume":"13","author":"JL Ghim","year":"2019","unstructured":"Ghim JL, Phuong NTT, Kim MJ, et al. Pharmacokinetics of fixed-dose combination of atorvastatin and metformin compared with individual tablets. Drug Des Dev Ther. 2019;13:1623\u201332. https:\/\/doi.org\/10.2147\/DDDT.S193254.","journal-title":"Drug Des Dev Ther"},{"issue":"4","key":"2869_CR48","doi-asserted-by":"publisher","first-page":"190","DOI":"10.12793\/tcp.2017.25.4.190","volume":"25","author":"YK Choi","year":"2017","unstructured":"Choi YK, Park SE, Kim EY, et al. Pharmacokinetics of atorvastatin and sustained-release metformin fixed-dose combination tablets: two randomized, open-label, 2-way crossover studies in healthy male subjects under fed conditions. Transl Clin Pharmacol. 2017;25(4):190\u20135. https:\/\/doi.org\/10.12793\/tcp.2017.25.4.190.","journal-title":"Transl Clin Pharmacol"},{"issue":"2","key":"2869_CR49","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/cpdd.787","volume":"10","author":"K Gundlach","year":"2021","unstructured":"Gundlach K, Wolf K, Salem I, Randerath O, Seiler D. Safety of candesartan, amlodipine, and atorvastatin in combination: interaction study in healthy subjects. Clin Pharmacol Drug Dev. 2021;10(2):190\u20137. https:\/\/doi.org\/10.1002\/cpdd.787.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"9","key":"2869_CR50","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.3109\/03639045.2012.725732","volume":"39","author":"JY Jeon","year":"2013","unstructured":"Jeon JY, Im YJ, Kim Y, et al. Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers. Drug Dev Ind Pharm. 2013;39(9):1296\u20139. https:\/\/doi.org\/10.3109\/03639045.2012.725732.","journal-title":"Drug Dev Ind Pharm"},{"key":"2869_CR51","doi-asserted-by":"publisher","first-page":"n1537","DOI":"10.1136\/bmj.n1537","volume":"374","author":"T Cai","year":"2021","unstructured":"Cai T, Abel L, Langford O, et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ. 2021;374:n1537. https:\/\/doi.org\/10.1136\/bmj.n1537.","journal-title":"BMJ"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02869-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02869-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02869-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T10:33:36Z","timestamp":1719570816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02869-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2869"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02869-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"9 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MinYoung Kim is an employee of Chong Kun Dang Pharm. Corp., Yongin, Republic of Korea. The other authors (Jae Hoon Kim, Ji Hye Song, Jang Hee Hong, Jung Sunwoo and Jin-Gyu Jung) declare no conflict of interest in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"These studies were conducted in accordance with the Declaration of Helsinki and Korean Good Clinical Practice and the International Conference on Harmonization and the study protocol was approved by the MFDS and the Chungnam National University Hospital IRB (study\u00a01: IRB No. CNUH 2020-06-031, study\u00a02: IRB No. CNUH 2020-09-117). Both studies\u00a01 and 2 were registered at ClinicalTrials.gov (study\u00a01: NCT04478097; study\u00a02: NCT04627207). All study participants gave informed consent. The informed consent form was reviewed and approved by the MFDS and the IRB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}